Trial Profile

A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SRF 231 (Primary)
Indications Chronic lymphocytic leukaemia; Haematological malignancies; Lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Surface Oncology

Most Recent Events

19 Oct 2020 Status changed from active, no longer recruiting to completed.
31 May 2020 Interim results (as of 11 Jan 2020; n=46) assessing safety of SRF231 in patients with advanced solid and hematologic malignancies, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
14 May 2020 According to a Surface Oncology media release, the company expects to present data from this trial at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com